SYLVIA AND CHARLES VIERTEL CHARITABLE FOUNDATION MARKS 30 YEARS MILESTONE IN FUNDING RESEARCH New Fellowships to researchers in cancer metastasis, epigenomics and AI in early disease diagnosis & management
With
Associate Professor Paul Ekert, Co-Chair,
Medical Advisory Board, Sylvia and Charles Viertel Charitable Foundation
SEGMENT
Filmed in Sydney, Melbourne & Adelaide | December 2025
One of Australia’s largest charitable foundations, the Sylvia and Charles Viertel Charitable Foundation, is celebrating three decades of transforming Australian healthcare – with more than $90 million invested in medical research and a legacy of breakthroughs that are saving lives. Viertel Fellowships support some of Australia’s best and brightest researchers and clinicians, with 70 Fellowships awarded to date.
In late October 2025, the Sylvia and Charles Viertel Charitable Foundation, in association with Bellberry, announced the recipients of the 2025 Viertel Senior Medical Research Fellowships. Three Australian mid-career researchers who are advancing solutions for major illnesses including cancer, cardiovascular disease, and neurodegenerative diseases. The 2025 Viertel Senior Medical Research Fellows, who will each receive $1.375 million over five years to support their work, are:
- Dr Joanna Achinger-Kawecka, SAiGENCI for her work in advancing cancer therapy utilising innovative 3D chromatin structure mapping technology.
- Dr Dustin Flanagan, Monash Biomedicine Discovery Institute, Monash University, for addressing the impact of direct cell damage on gastric cancer initiation and progression.
- Associate Professor Zongyuan Ge, Monash AIM for Health Lab, Monash University for developing a personalised healthcare model integrating diverse patient information collected over time via AI. He is the recipient of a Bellberry-Viertel Senior Medical Research Fellowship.
The Viertel Foundation over 30 years has had significant impact in medical research, including
- Awarding 70 fellowships since 1995, each currently providing $1.375 million over five years to support Australia’s top mid-career researchers.
- 162 Clinical Investigator Awards providing $90,000 over one year have been granted, supporting early-career clinicians and stimulating clinical research across Australia.
- Research infrastructure grants totalling $2.45 million have been awarded, recognising the importance of establishing and maintaining the facilities required for world-class research environments.
- The combined total value of the Clinical Investigator Awards, the Fellowships, and infrastructure grants – including the most recent awards has reached $90,001,250. This substantial investment underscores the Foundation’s enduring commitment to advancing medical research and improving health outcomes for Australians.
- Funding has enabled breakthroughs in cancer, infectious diseases, respiratory illnesses, dementia, stem cell research, and more – directly impacting millions of Australians each year.
Source: Adapted from Equity Trustees media release
Photo Credit: Charles Viertel Photo, Queensland Eye Institute
Photo Credit: AAHMS Gala Dinner, Canberra November 2025, Australian Academy of Health and Medical Sciences
-
Addressing the perinatal mental health clinician shortage
Perinatal depression and anxiety (PNDA) impacts 100,000 Australians each year, equating to one in five mums and one in ten dads, with PNDA costing Australia $877 million annually. To address the nationwide shortage of specialist perinatal mental health clinicians, Gidget Foundation Australia has partnered with Federation University to launch the Graduate Diploma in Perinatal Mental Health.
-
Australian Teletrial Program reaches significant milestones in trials and participants
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements.
-
Improved access to technology needed for people with Type 2 Diabetes needing insulin
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.
